| Keywords: |
genetics; antineoplastic agents; antineoplastic agent; imatinib; protein kinase inhibitor; drug effect; drug resistance; drug resistance, neoplasm; abelson kinase; chronic myeloid leukemia; oncogene proteins v-abl; pyrimidines; time; time factors; protein kinase inhibitors; economics; drug antagonism; drug combination; drug therapy, combination; piperazines; piperazine derivative; pyrimidine derivative; leukemia, myelogenous, chronic, bcr-abl positive; multidrug resistance; drug resistance, multiple; benzamide derivative; benzamides
|
